Subtype
Urinary System Carcinoma
CI-CAN-00004182Explore in graph →
670 active trials25 approved drugs87 evidence items
- NCIt
- C181197
Loading cancer entity…
Loading cancer entity…
Subtype
CI-CAN-00004182Explore in graph →
Clinical trials
2,394 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (391)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT00004856 | Trastuzumab in Treating Patients With Previously Treated, Locally Advanced, or Metastatic Cancer of the Urothelium | terminated | Phase 2 | 40 | National Cancer Institute (NCI)NIH | 1 | May 3, 2013 | clinicaltrials |
| NCT00491075 | Pemetrexed Plus Gemcitabine in Renal Cell Cancer | terminated | Phase 2 | 16 | M.D. Anderson Cancer CenterOTHER | 1 | Apr 24, 2013 | clinicaltrials |
| NCT01616186 |
| Everolimus/Sorafenib or Sunitinib in Patients With Metastatic Renal Cell Carcinoma (RCC) |
| withdrawn |
| Phase 2 |
| 0 |
| Andrea HarzstarkOTHER |
| 0 |
| Apr 8, 2013 |
| clinicaltrials |
| NCT00182702 | Ixabepilone in Treating Patients With Metastatic, Recurrent, or Unresectable Kidney Cancer | completed | Phase 2 | 37 | National Cancer Institute (NCI)NIH | 1 | Mar 25, 2013 | clinicaltrials |
| NCT00494091 | Study Evaluating The Safety, Efficacy & Pharmacokinetics Of Temsirolimus(CCI-779) In Subjects With Advanced Renal Cell Carcinoma | completed | Phase 2 | 82 | PfizerINDUSTRY | 3 | Mar 21, 2013 | clinicaltrials |
| NCT00490698 | Zoledronate With Atorvastatin in Renal Cell Carcinoma | completed | Phase 2 | 11 | M.D. Anderson Cancer CenterOTHER | 1 | Mar 18, 2013 | clinicaltrials |
| NCT00272649 | Study Testing the Biologic Activity and Safety of an Immunotherapeutic in Patients With Newly Diagnosed Stage IV Kidney Cancer | completed | Phase 1 / Phase 2 | 22 | Argos TherapeuticsINDUSTRY | 2 | Mar 14, 2013 | clinicaltrials |
| NCT00429026 | Conditioning Regimen in Nonmyeloablative Allogeneic Hematopoietic Stem Cell Transplantation | terminated | Phase 2 | 40 | M.D. Anderson Cancer CenterOTHER | 1 | Mar 4, 2013 | clinicaltrials |
| NCT00060307 | Erlotinib in Treating Patients With Locally Advanced or Metastatic Papillary Renal Cell Cancer | completed | Phase 2 | 40 | National Cancer Institute (NCI)NIH | 1 | Feb 28, 2013 | clinicaltrials |
| NCT00101114 | Sorafenib and Interferon Alfa in Treating Patients With Metastatic or Unresectable Kidney Cancer | completed | Phase 2 | 55 | National Cancer Institute (NCI)NIH | 1 | Feb 28, 2013 | clinicaltrials |
| NCT00087984 | RNA-Loaded Dendritic Cell Cancer Vaccine | completed | Phase 1 / Phase 2 | 26 | Argos TherapeuticsINDUSTRY | 2 | Feb 18, 2013 | clinicaltrials |
| NCT00619268 | Combination of Temsirolimus and Bevacizumab in Patient With Metastatic Renal Cell Carcinoma(TORAVA) | completed | Phase 2 | 160 | Centre Leon BerardOTHER | 1 | Feb 15, 2013 | clinicaltrials |
| NCT00557609 | Phase 2 Study in Patients With MiT Tumors | completed | Phase 2 | 47 | ArQule, Inc., a subsidiary of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc. (Rahway, NJ USA)INDUSTRY | 3 | Feb 8, 2013 | clinicaltrials |
| NCT00193258 | Bevacizumab, Erlotinib, and Imatinib in the Treatment of Advanced Renal Cell Carcinoma | completed | Phase 1 / Phase 2 | 94 | SCRI Development Innovations, LLCOTHER | 0 | Jan 31, 2013 | clinicaltrials |
| NCT00021099 | Ixabepilone in Treating Patients With Advanced Urinary Tract Cancer | completed | Phase 2 | 45 | National Cancer Institute (NCI)NIH | 1 | Jan 24, 2013 | clinicaltrials |
| NCT00032188 | Interleukin-2 and Bryostatin 1 in Treating Patients With Advanced Kidney Cancer | completed | Phase 2 | 65 | National Cancer Institute (NCI)NIH | 1 | Jan 24, 2013 | clinicaltrials |
| NCT00009919 | SU5416 in Treating Patients With Metastatic Kidney Cancer That Has Not Responded to Previous Treatment | terminated | Phase 2 | 50 | National Cancer Institute (NCI)NIH | 1 | Jan 23, 2013 | clinicaltrials |
| NCT00006486 | Carboxyamidotriazole in Treating Patients With Metastatic Kidney Cancer | completed | Phase 2 | 335 | National Cancer Institute (NCI)NIH | 1 | Jan 16, 2013 | clinicaltrials |
| NCT00005831 | Trastuzumab and Combination Chemotherapy in Treating Patients With Locally Recurrent or Metastatic Urinary Tract Cancer | completed | Phase 2 | 40 | National Cancer Institute (NCI)NIH | 1 | Jan 14, 2013 | clinicaltrials |
| NCT00486538 | Study of ABT-869 in Subjects With Advanced Renal Cell Carcinoma Who Have Previously Received Treatment With Sunitinib | completed | Phase 2 | 53 | AbbVie (prior sponsor, Abbott)INDUSTRY | 2 | Jan 4, 2013 | clinicaltrials |
| NCT00322699 | Sequential Whole Bladder Photodynamic Therapy (WBPDT) in the Management of Superficial Bladder Cancer | completed | Phase 1 / Phase 2 | 22 | North Florida/South Georgia Veterans Health SystemOTHER | 1 | Oct 26, 2012 | clinicaltrials |
| NCT00338884 | Safety And Effectiveness Of Daily Dosing With 37.5 mg Sunitinib Malate In Patients With Advanced Kidney Cancer | completed | Phase 2 | 120 | PfizerINDUSTRY | 6 | Aug 31, 2012 | clinicaltrials |
| NCT00030992 | BMS 247550 to Treat Kidney Cancer | completed | Phase 2 | 102 | National Cancer Institute (NCI)NIH | 1 | Aug 20, 2012 | clinicaltrials |
| NCT01158534 | Celecoxib and Recombinant Interferon Alfa-2b in Metastatic Kidney Cancer Who Have Undergone Surgery | completed | Phase 2 | 17 | Case Comprehensive Cancer CenterOTHER | 1 | Aug 7, 2012 | clinicaltrials |
| NCT00282048 | Study Of AG-013736 In Patients With Refractory Metastatic Renal Cell Cancer | completed | Phase 2 | 62 | PfizerINDUSTRY | 1 | Jul 31, 2012 | clinicaltrials |
| NCT01070186 | Study of Sunitinib in Subjects With High Risk Renal Cell Carcinoma | withdrawn | Phase 2 | 0 | Jonsson Comprehensive Cancer CenterOTHER | 0 | Jul 31, 2012 | clinicaltrials |
| NCT00523159 | IMA901 in Advanced Renal Cell Carcinoma Patients With Measurable Disease(IMA901-202) | completed | Phase 2 | 68 | Immatics Biotechnologies GmbHINDUSTRY | 10 | Jul 10, 2012 | clinicaltrials |
| NCT00100685 | Study of M200 (Volociximab) in Patients With Metastatic Renal Cell Carcinoma (RCC) | terminated | Phase 2 | 48 | AbbottINDUSTRY | 1 | Apr 27, 2012 | clinicaltrials |
| NCT01246817 | Temsirolimus-RCC-imaging | unknown | Phase 2 | 51 | Radboud University Medical CenterOTHER | 1 | Apr 11, 2012 | clinicaltrials |
| NCT00485563 | A Phase II Study of EC17 (Folate-hapten Conjugate) in Patients With Progressive Metastatic Renal Cell Carcinoma | terminated | Phase 2 | 12 | EndocyteINDUSTRY | 1 | Mar 8, 2012 | clinicaltrials |
| NCT00561912 | Low Dose Decitabine + Interferon Alfa-2b in Advanced Renal Cell Carcinoma | terminated | Phase 2 | 2 | M.D. Anderson Cancer CenterOTHER | 1 | Dec 26, 2011 | clinicaltrials |
| NCT00197860 | Dendritic Cell Based Therapy of Renal Cell Carcinoma | completed | Phase 1 / Phase 2 | 40 | Inge Marie SvaneOTHER | 1 | Nov 23, 2011 | clinicaltrials |
| NCT00036036 | Study of CP-461 in Patients With Advanced Renal Cell Cancer | completed | Phase 2 | 14 | Astellas Pharma IncINDUSTRY | 1 | Oct 17, 2011 | clinicaltrials |
| NCT00267748 | Sunitinib Malate Schedule 4/2 vs. Sunitinib Malate Continuous Dosing As First-Line Therapy For Metastatic Renal Cell Cancer (RCC) | completed | Phase 2 | 317 | PfizerINDUSTRY | 1 | Sep 5, 2011 | clinicaltrials |
| NCT00113529 | Study Of SU011248 Plus Gefitinib (Iressa) In Patients With Advanced Renal Cell Carcinoma | completed | Phase 1 / Phase 2 | 42 | PfizerINDUSTRY | 1 | Aug 29, 2011 | clinicaltrials |
| NCT00444314 | Phase 2 Study of Panzem® NCD Alone and Combined With Sunitinib Malate in Patients With Metastatic Renal Cell Carcinoma | completed | Phase 2 | 82 | CASI pharmaceuticals, Inc.INDUSTRY | 1 | Aug 4, 2011 | clinicaltrials |
| NCT01069770 | Neoadjuvant Sunitinib Treatment for Metastatic Clear Cell Renal Cell Carcinoma (RCC) | unknown | Phase 2 | 32 | Korean Urological Oncology SocietyOTHER | 1 | Jun 23, 2011 | clinicaltrials |
| NCT01219751 | Trial Of Sunitinib In Advanced Non-Clear Cell Type Renal Cell Carcinoma | unknown | Phase 2 | 35 | Asan Medical CenterOTHER | 1 | Jun 17, 2011 | clinicaltrials |
| NCT00862303 | DC Vaccine Therapy Combined With Cytokine-Induced Killer Cell in Treating Patients With Renal Cell Carcinoma | unknown | Phase 1 / Phase 2 | 100 | Fuzhou General HospitalOTHER | 1 | Mar 8, 2011 | clinicaltrials |
| NCT00330707 | Combined Use of BCG and Interferon Alpha in Bladder Cancer | completed | Phase 2 / Phase 3 | 140 | National University Hospital, SingaporeOTHER | 1 | Mar 4, 2011 | clinicaltrials |
| NCT00065572 | Exploratory Study to Assess the Biological Activity of ZD6126 in Subjects With Newly Diagnosed Metastatic Renal Cell Carcinoma (Stage IV) | suspended | Phase 2 | — | AstraZenecaINDUSTRY | 1 | Jan 26, 2011 | clinicaltrials |
| NCT00661609 | A Phase II Study of AZD4877 (a Novel Anti-mitotic Agent) in Advanced Bladder Cancer | completed | Phase 2 | 54 | AstraZenecaINDUSTRY | 5 | Jan 12, 2011 | clinicaltrials |
| NCT01240005 | Cytokine Induced Killer Cells Stimulated by DC Immunotherapy for Renal Cell Carcinoma | unknown | Phase 1 / Phase 2 | 30 | Qingdao UniversityOTHER | 1 | Nov 15, 2010 | clinicaltrials |
| NCT00077974 | A Pivotal Study Of SU011248 In The Treatment Of Patients With Cytokine-Refractory Metastatic Renal Cell Carcinoma. | completed | Phase 2 | 106 | PfizerINDUSTRY | 1 | Oct 13, 2010 | clinicaltrials |
| NCT01176552 | Granulocyte-macrophage Colony-stimulating Factor, Interferon and Interleukin-2 as Adjuvant Treatment for Renal Cancer | completed | Phase 2 | 35 | Kidney Cancer Research BureauOTHER | 1 | Aug 24, 2010 | clinicaltrials |
| NCT01182142 | Study of Capecitabine in Metastatic Non-clear Cell Renal Cell Carcinoma (RCC) Patients | completed | Phase 2 | 51 | Kidney Cancer Research BureauOTHER | 1 | Aug 24, 2010 | clinicaltrials |
| NCT00848640 | Study of Sorafenib in Patients With Advanced Renal Cell Carcinoma(MERITS) | completed | Phase 2 | 75 | Egyptian Foundation For Cancer ResearchOTHER | 1 | May 26, 2010 | clinicaltrials |
| NCT00610389 | Phase II Study With Immunotherapy With Dendritic Cells and Tumor Infiltrating Lymphocytes in Solid Tumors | unknown | Phase 2 | 27 | Clinica Universidad de Navarra, Universidad de NavarraOTHER | 1 | May 10, 2010 | clinicaltrials |
| NCT00254540 | Study of SU011248 in Patients With Advanced Kidney Cancer | completed | Phase 2 | 51 | PfizerINDUSTRY | 1 | Feb 23, 2010 | clinicaltrials |
Data updated 22 days agoSource updated May 3, 2013source: clinicaltrials